RecruitingPhase 3NCT06524882

Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age

A Randomized Trial of Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age


Sponsor

Jaeb Center for Health Research

Enrollment

252 participants

Start Date

Oct 22, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization. At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logMAR line (5 letters) or more, will be offered randomization to Luminopia or Vivid Vision dichoptic therapy and if they accept, followed forward with visits at 27- and 36-weeks post-randomization. The study will end for all other participants at 18 weeks.


Eligibility

Min Age: 8 YearsMax Age: 12 Years

Inclusion Criteria44

  • Age 8 to \<13 years.
  • VA, measured in each eye without cycloplegia in current refractive correction (if applicable) using the E-ETDRS VA protocol on a study-approved device displaying single surrounded optotypes, as follows:
  • VA in the amblyopic eye 20/40 to 20/200 inclusive (33 to 72 letters with E-ETDRS).
  • VA in the fellow eye 20/25 or better (≥ 78 letters with E-ETDRS).
  • Interocular difference ≥ 3 logMAR lines (≥ 15 letters) i.e., amblyopic eye VA at least 3 logMAR lines worse than fellow eye VA).
  • Amblyopia associated with strabismus, anisometropia, or both (previously treated or untreated).
  • Criteria for strabismic amblyopia: At least one of the following must be met:
  • Presence of a heterotropia on examination at distance or near fixation (with optical correction), must be \<=5 prism diopters (∆) by SPCT at distance and near fixation.
  • Documented history of strabismus which is no longer present (which in the judgment of the investigator could have caused amblyopia).
  • Criteria for anisometropia: At least one of the following criteria must be met:
  • ≥1.00 D difference between eyes in spherical equivalent (SE).
  • ≥1.50 D difference in astigmatism between corresponding meridians in the two eyes.
  • Criteria for combined-mechanism: Both of the following criteria must be met:
  • A criterion for strabismus is met (see above).
  • ≥1.00 D difference between eyes in SE OR ≥1.50 D difference in astigmatism between corresponding meridians in the two eyes.
  • No more than 2 weeks (cumulative) of prior dichoptic treatment
  • No treatment with cycloplegic eyedrops (e.g., atropine) in the past 2 weeks; other treatments allowed up to enrollment but then must be discontinued.
  • Refractive correction is required (single vision lenses or contact lenses) for any of the following refractive errors based on a cycloplegic refraction completed within the last 7 months:
  • Hypermetropia of 2.50 D or more by SE
  • Myopia of amblyopic eye of 0.50D or more SE
  • Astigmatism of 1.00D or more
  • Anisometropia of more than 0.50D SE
  • NOTE: Children with cycloplegic refractive errors that do not fall within the requirements above for refractive correction may be given refractive correction at investigator discretion but must follow the study-specified prescribing guidelines, as detailed below.
  • NOTE: Monocular or binocular contact lens wear is allowed provided the contact lenses meet the refractive error correction requirements below. For each child, all testing must be performed using the same form of optical correction (i.e., no changing between contacts and spectacles).
  • Spectacles/contact lens correction prescribing instructions referenced to the cycloplegic refraction completed within the last 7 months:
  • SE must be within 0.50D of fully correcting the anisometropia (if new glasses are prescribed, reduction in plus sphere must be symmetric in the two eyes).
  • SE must not be under corrected by more than 1.50D SE.
  • Cylinder power in both eyes must be within 0.50D of fully correcting the astigmatism.
  • Axis must be within +/- 10 degrees if cylinder power is ≤1.00D, and within +/- 5 degrees if cylinder power is \>1.00D.
  • Myopia must not be under corrected by more than 0.25D or over corrected by more than 0.50D SE, and any change must be symmetrical in the two eyes.
  • Spectacles/contact lens correction (with or without other treatment such as patching) meeting the above criteria must be worn:
  • For at least 18 weeks OR until VA stability is documented (defined as \<1-line change by the same testing method measured on 2 consecutive exams at least 9 weeks apart).
  • For determining VA stability (non-improvement):
  • The first of two measurements may be made 1) in current correction, or 2) in trial frames with or without cycloplegia or 3) without correction (if new correction is prescribed),
  • The second measurement must be made without cycloplegia in the correct spectacles/contact lens correction that has been worn for at least 9 weeks.
  • NOTE: Because this determination is a pre-randomization, the method of measuring VA is not mandated.
  • Participant is willing to wear a headset.
  • Participant is willing to continue full-time spectacles/contact lens wear (if needed).
  • Interpupillary distance of 52mm to 72mm inclusive.
  • Investigator is willing to prescribe continued spectacles/contact lens correction (if needed) or either dichoptic device per protocol.
  • Participant is willing to accept assignment to either continued spectacles/ contact lens wear alone, dichoptic movies/shows (view 1 hour per day 6 days per week) OR dichoptic games (play approximately 25 minutes per day, 6 days per week) for 19 weeks.
  • Parent understands the protocol and is willing to accept randomization.
  • Parent has phone (or access to phone) and is willing to be contacted by JAEB Center staff.
  • Relocation outside of area of an active PEDIG site for this study within the next 36 weeks is not anticipated.

Exclusion Criteria10

  • Heterotropia more than 5∆ at distance or near (measured by SPCT in current correction)
  • Prism greater than a total of 8 diopters horizontal and 1 diopter vertical in the refractive correction at time of enrollment.
  • Current bifocal spectacles (eligible only if bifocal discontinued 2 weeks prior to enrollment).
  • Myopia greater than -6.00D spherical equivalent in either eye.
  • Ocular co-morbidity that may reduce VA determined by an ocular examination performed within the past 7 months (Note: nystagmus per se does not exclude the participant if the above visual acuity criteria are met using patch occlusion. Fogging is not permitted).
  • Diplopia more than once per week over the last week prior to enrollment by parental report.
  • History of light-induced seizures.
  • Known simulator sickness.
  • Severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Participants with mild speech delay or reading and/or learning disabilities are not excluded.
  • Immediate family member (biological or legal guardian, child, sibling, parent) of investigative site personnel directly affiliated with this study or an employee of the JAEB center for Health Research.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEVivid Vision

dichoptic video games played through a virtual reality headset

DEVICELuminopia

dichoptic movies/shows shown through a virtual reality headset

DEVICEOptical Correction

Glasses prescribed at investigator discretion


Locations(58)

UAB Pediatric Eye Care; Birmingham Health Care

Birmingham, Alabama, United States

Midwestern University Eye Institute

Glendale, Arizona, United States

Phoenix Children's Medical Group - Ophthalmology

Scottsdale, Arizona, United States

University of Arizona

Tucson, Arizona, United States

Arkansas Childrens

Little Rock, Arkansas, United States

McFarland Eye Care Center

Little Rock, Arkansas, United States

University Eye Center at Ketchum Health

Anaheim, California, United States

Univ. of California- Berkeley

Berkeley, California, United States

Univ of California, Irvine- Gavin Herbert Eye Institute

Irvine, California, United States

Stanford University

Palo Alto, California, United States

Western University College of Optometry

Pomona, California, United States

University of California, Davis

Sacramento, California, United States

University of California San Francisco Department of Ophthalmology

San Francisco, California, United States

Nova Southeastern University College of Optometry, The Eye Institute

Fort Lauderdale, Florida, United States

University of South Florida (USF) Eye

Tampa, Florida, United States

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Illinois College of Optometry

Chicago, Illinois, United States

Midwestern University Eye Institute

Downers Grove, Illinois, United States

Progressive Eye Care

Lisle, Illinois, United States

Indiana School of Optometry

Bloomington, Indiana, United States

University of Iowa

Iowa City, Iowa, United States

University of Kansas Dept of Ophthalmology

Prairie Village, Kansas, United States

Greater Baltimore Medical Center

Baltimore, Maryland, United States

Wilmer Eye Institute

Baltimore, Maryland, United States

New England College of Optometry

Boston, Massachusetts, United States

Boston Medical Center

Boston, Massachusetts, United States

Boston Children's Hospital Waltham

Boston, Massachusetts, United States

Michigan College of Optometry at Ferris State Univ

Big Rapids, Michigan, United States

Pediatric Ophthalmology, P.C.

Grand Rapids, Michigan, United States

Zenith Vision Development Center

Duluth, Minnesota, United States

University of Minnesota-Minnesota Lions Children's Eye Clinic

Minneapolis, Minnesota, United States

Mayo Clinic Department of Ophthalmology

Rochester, Minnesota, United States

PineCone Vision Center

Sartell, Minnesota, United States

Children's Mercy Hospitals and Clinics

Kansas City, Missouri, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

NYU Langone Health

New York, New York, United States

State University of New York, College of Optometry

New York, New York, United States

University of North Carolina

Chapel Hill, North Carolina, United States

Duke University Eye Center

Durham, North Carolina, United States

University of North Dakota

Grand Forks, North Dakota, United States

Cincinnati Children's Hospital

Cincinnati, Ohio, United States

Cole Eye Institute

Cleveland, Ohio, United States

Ohio State University College of Optometry

Columbus, Ohio, United States

Rainbow Babies and Children's Hospital Dept of Ophth

Mayfield Heights, Ohio, United States

River View Family Eyecare

Albany, Oregon, United States

OHSU Casey Eye Institute

Portland, Oregon, United States

Pediatric Ophthalmology of Erie

Erie, Pennsylvania, United States

Conestoga Eye

Lancaster, Pennsylvania, United States

Wills Eye Hospital

Philadelphia, Pennsylvania, United States

Salus University/Pennsylvania College of Optometry

Philadelphia, Pennsylvania, United States

Storm Eye Institute

Mt. Pleasant, South Carolina, United States

Southern College of Optometry

Memphis, Tennessee, United States

Baylor College of Medicine

Houston, Texas, United States

University of Houston - College of Optometry

Houston, Texas, United States

University of Houston College of Optometry

Houston, Texas, United States

San Antonio Eye Center

San Antonio, Texas, United States

Virginia Pediatric Eye Center

Norfolk, Virginia, United States

Spokane Eye Clinical Research

Spokane, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06524882


Related Trials